Synergistic Therapeutic System for Corneal Endothelial Diseases
Legal Citation
Summary of the Inventive Concept
A novel system integrating (T)EW-7197 with distinct technologies such as AI, IoT, blockchain, and nanomaterials to provide more effective and personalized treatment options for corneal endothelial diseases.
Background and Problem Solved
The original patent disclosed the use of (T)EW-7197 for treating or preventing corneal endothelial diseases. However, the patent did not address the limitations of current treatment methods, such as the lack of personalized dosing regimens, inefficient data management, and limited therapeutic delivery options. The new inventive concept addresses these limitations by combining (T)EW-7197 with innovative technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The synergistic therapeutic system comprises a combination of (T)EW-7197 and at least one of the following: a blockchain-based data management module, an AI-driven dosing regimen, a biodegradable polymer matrix, a portable IoT-enabled device, or a novel nanomaterial-based delivery system. The system enables personalized treatment of corneal endothelial diseases, real-time monitoring of corneal endothelial cell density, and targeted release of the therapeutic compound to the corneal endothelium.
Novelty and Inventive Step
The new claims introduce a synergistic combination of (T)EW-7197 with distinct technologies, which is not obvious from the original patent. The integration of these technologies provides a novel and non-obvious solution for treating or preventing corneal endothelial diseases.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, various blockchain architectures, or diverse nanomaterials for therapeutic delivery. Additionally, the system could be adapted for treating other ocular diseases or conditions.
Potential Commercial Applications and Market
The synergistic therapeutic system has significant commercial potential in the ophthalmology market, particularly for the treatment of corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy. The system's ability to provide personalized treatment options, real-time monitoring, and targeted therapeutic delivery could revolutionize the field of ophthalmology and improve patient outcomes.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Ophthalmological therapeutics, specifically corneal endothelial disease treatment, involving pharmaceutical compositions, medical device technologies, and personalized medical interventions
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or pharmaceutical scientist with expertise in ophthalmology, biotechnology, and medical device design, holding advanced degrees in pharmacology, biomedical engineering, or related fields, with knowledge of drug delivery systems and emerging medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies and advanced delivery mechanisms with known therapeutic compounds represents a predictable evolution of medical treatment strategies. The combination of (T)EW-7197 with blockchain, AI, IoT, and nanomaterial technologies reflects standard technological convergence in personalized medicine. These variations represent incremental improvements that would be obvious to a skilled practitioner seeking to enhance treatment efficacy and patient monitoring.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,544 |
|---|---|
| Title | Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases |
| Assignee(s) | SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHA |